Please login to the form below

Not currently logged in


This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

GSK’s says depot HIV injection works over three years

GSK’s says depot HIV injection works over three years

Earlier this year, GSK won approval for oral two-drug regimen Juluca – based on integrase inhibitor Tivicay (dolutegravir) and rilpivirine – that aims to provide effective control of HIV with a single ... FLAIR is looking at monthly dosing in

Latest news

More from news
Approximately 8 fully matching, plus 46 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’ s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...